Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Patients with COVID-19 Associated Respiratory Illness

SARPAC trial initiated at the University Hospital Ghent in Belgium

Lexington, MA – March 24, 2020 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced that Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent to treat patients with respiratory illness associated with COVID-19.  Major medical centers in Germany, Italy and Spain are considering joining the study.  The study will evaluate the effect ...

Continue Reading →
0

Partner Therapeutics (PTx) Announces the Appointment of John McManus as Chief Business Officer

Former Aeolus CEO will lead business development and government relations

LEXINGTON, Mass., Nov. 7, 2019 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that it appointed John McManus to serve as the company’s Chief Business Officer. In his role as CBO, Mr. McManus will oversee business development activities and government relations for PTx and serve on the Company’s executive management team.

Mr. McManus has over 20 years of leadership experience in the biopharmaceutical industry that includes leading the ...

Continue Reading →
0

Partner Therapeutics Receives Orphan Drug Designation for Leukine® (sargramostim)

 

LEXINGTON, Mass., Sept. 19, 2019 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.

Melanoma is the most aggressive form of skin cancer and rates of melanoma have been rising for the past 30 years. The American Cancer Society estimates 96,480 new melanoma cases will be ...

Continue Reading →
0

Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis

 

LEXINGTON, MA – Nov 6th, 2018/ PR Newswire/ – Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP). Leukine works by stimulating the production of white blood cells including neutrophils, monocytes/macrophages and myeloid-derived dendritic cell and promoting their ability to function.

PAP is a rare syndrome characterized by ...

Continue Reading →
0

Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome

 

LEXINGTON, Mass., June 6, 2018 /PRNewswire/

Commercial-stage cancer biotech company, Partner Therapeutics, Inc. (PTx), announced the recent FDA approval of Leukine for the treatment of adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS). Leukine is the first drug for H-ARS to demonstrate an improvement in survival when initiated 48 hours after radiation exposure.

Acute Radiation Syndrome (ARS) (sometimes known as radiation toxicity or radiation sickness) is an acute illness caused by ...

Continue Reading →
0

Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine®

 

CHARLOTTE, N.C., May 24, 2018 08:00 AM 

(BUSINESS WIRE)– Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx), an integrated biopharmaceutical company. The agreement names Tanner Pharma Group as a distributor of Leukine® (sargramostim) in areas outside of the United States and Canada where the product is not yet registered. Leukine® (sargramostim) is used to help increase ...

Continue Reading →
0

Partner Therapeutics (PTx) Announces the Appointment of Ellen Hukkelhoven Ph.D. and Terry Gould to its Board of Directors

Add their extensive experience and networks to PTx team

BOSTON, March 7, 2018-PRNewswire

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today the appointment of Ellen Hukkelhoven and Terry Gould to the company’s Board of Directors. Dr. Hukkelhoven and Mr. Gould join the company’s founders Bob Mulroy and Debasish Roychowdhury as directors.

Dr. Ellen Hukkelhoven is a Senior Analyst at Perceptive Advisors, a leading healthcare investment firm. Perceptive invests in highly innovative therapies aimed at the treatment of true unmet medical needs. The ...

Continue Reading →
0

Partner Therapeutics (PTx) Announces the Appointment of Colleen Mockbee as Chief Development Officer

Former Lilly Executive will oversee Development, Regulatory Affairs and Quality

BOSTON, Feb. 22, 2018 /PRNewswire/

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it appointed Colleen Mockbee to serve as the company’s Chief Development Officer. In her role as CDO, Ms. Mockbee will oversee development, regulatory and quality activities and serve on the Company’s executive management team.

Ms. Mockbee joins PTx following a 20-year career as a leader and executive overseeing multiple areas of drug development at Eli Lilly and Company. ...

Continue Reading →
0

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

Purchase includes Lynnwood, WA Biologics Manufacturing Facility 

BOSTON, MA – February 1, 2018/ PR Newswire/

Boston-based cancer company Partner Therapeutics, Inc. (PTx) announced today that it has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the ...

Continue Reading →
0

Partner Therapeutics, Inc. (PTx) Closes $60 Million Financing

Funds to support pipeline development and commercial operations 

BOSTON, MA – February 1, 2018/ PR Newswire/

Partner Therapeutics, Inc. (PTx) announced today the closing of a Series A financing to support the launch and growth of the company. PTx is an oncology company focused on the development and commercialization of approved and late-stage therapies that improve treatment outcomes and reduce the total cost of care.

The financing totaled $60 million and was led by a group of pre-eminent biopharma investors, including Perceptive Advisors, ...

Continue Reading →
0
Page 1 of 2 12